Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (NCT07388550) titled 'Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)' on Feb. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Condition:
Post-Acute COVID-19 Syndrome
Intervention:
Drug: Keytruda
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: February 9, 2026
Target Sample Size: 15
Countries of Recruitment:
United States
To know more, vis...